Proteogenomic data and resources for pan-cancer analysis

Y Li, Y Dou, FDV Leprevost, Y Geffen, AP Calinawan… - Cancer cell, 2023 - cell.com
Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Deubiquitylating enzymes and drug discovery: emerging opportunities

JA Harrigan, X Jacq, NM Martin… - Nature reviews Drug …, 2018 - nature.com
More than a decade after a Nobel Prize was awarded for the discovery of the ubiquitin–
proteasome system and clinical approval of proteasome and ubiquitin E3 ligase inhibitors …

[HTML][HTML] Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

C Abbosh, AM Frankell, T Harrison, J Kisistok… - Nature, 2023 - nature.com
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells
persisting after curative intent therapy. The study of large patient cohorts incorporating …

GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels

CJ Liu, FF Hu, GY Xie, YR Miao, XW Li… - Briefings in …, 2023 - academic.oup.com
Cancer initiation and progression are likely caused by the dysregulation of biological
pathways. Gene set analysis (GSA) could improve the signal-to-noise ratio and identify …

A novel cuproptosis-related prognostic gene signature and validation of differential expression in clear cell renal cell carcinoma

Z Bian, R Fan, L Xie - Genes, 2022 - mdpi.com
Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of renal cell
carcinoma, which is characterized by metabolic reprogramming. Cuproptosis, a novel form …

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

A Rodriguez-Meira, R Norfo, S Wen, AL Chédeville… - Nature …, 2023 - nature.com
Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …

[HTML][HTML] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

A Bagaev, N Kotlov, K Nomie, V Svekolkin, A Gafurov… - Cancer cell, 2021 - cell.com
The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

[HTML][HTML] The genomic landscape of pediatric acute lymphoblastic leukemia

SW Brady, KG Roberts, Z Gu, L Shi, S Pounds, D Pei… - Nature …, 2022 - nature.com
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using
whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL …

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

A Ravi, MD Hellmann, MB Arniella, M Holton… - Nature …, 2023 - nature.com
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …

[HTML][HTML] Proteogenomic characterization of pancreatic ductal adenocarcinoma

L Cao, C Huang, DC Zhou, Y Hu, TM Lih, SR Savage… - Cell, 2021 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …